Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Prophylactic treatment with antiepileptic drugs is common practice following subarchnoid hemorrhage (SAH) and traumatic brain injury. However, commonly used antiepileptic drugs have multiple drug interactions, require frequent monitoring of serum levels, and are associated with adverse effects that may prompt discontinuation. In the current study, we test the hypothesis that levetiracetam, an anticonvulsant with favorable interaction and adverse event profiles, is neuroprotective in clinically relevant models of SAH and closed head injury (CHI).
A single intravenous dose of vehicle, low-dose (18 mg/kg), or high-dose (54 mg/kg) levetiracetam was administered intravenously followed CHI. Functional assessments were performed on a daily basis, and histological assessments performed at 24 hours. In a separate series of experiments, mice were randomized to receive in travenous administration of vehicle, low-dose, or high-dose levetiracetam every 12 hours for 3 days following SAH. Functional endpoints were assessed daily, followed by measurement of MCA luminal diameter on day 3.
A single dose of levetiracetam improved functional and histological outcomes after CHI. This effect appeared specific for levetiracetam and was not associated with fosphenytoin treatment. Treatment with levetiracetam also improved functional outcomes and reduced vasospasm following SAH.
Levetiracetam is neuroprotective in clinically relevant animal models of SAH and CHI. Levetiracetam may be a therapeutic alternative to phenytoin following acute brain injury in the clinical setting when seizure prophylaxis is indicated.
- Chang BS, Lowenstein DH. Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;60:10–16.
- Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990;323:497–502. CrossRef
- Korman LB, Olson MJ. Phenytoin-induced hepatitis, rhabdomyolysis, and renal dysfunction. Clin Pharm 1989;8:514–515.
- Conger LA, Grabski WJ. Dilantin hypersensitivity reaction. Cutis 1996;57(4):223–226.
- Patsalos PN. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2(8):473–481. CrossRef
- Browne TR, Kugler AR, Eldon MA. Pharmacology and pharma cokinetics of fosphenytoin. Neurology 1996;46(Suppl) 1:S7-S10.
- Naidech AM, Kreiter KT, Janua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 2005;36:583–587. CrossRef
- Klitgaard H, Matagne A, Gobert J, Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353:191–206. CrossRef
- Dooley M, Plosker GL, Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs 2000;60:871–893. CrossRef
- Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology 2003;5:704–706.
- Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002;136:659–672. CrossRef
- Hannon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral arteryocclusion model of focal cerebral ischemia. Seizure 2001;10:287–293. CrossRef
- Lynch JR, Pineda JA, Morgan D, et al. Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema, Ann Neurol 2002;51:113–117. CrossRef
- Lynch JR, Wang H, Mace B, et al. A novel therapeutic derived from apolipoprotein Ereduces brain inflammation and improves outcome after closed head injury. Exp Neurol 2005;192:109–116. CrossRef
- McGirt MJ, Lynch J, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm following subarachnoid hemorrhage. Stroke 2002;33:2950–2956. CrossRef
- Foda MA, Marmarou A. A new model of diffuse brain injury in rats. Part II: morphological characterization. J Neurosurg 1994;80:301–313.
- Marmarou A, Foda MA, van den brink W, Campbell J, Kita H, Demetriadou K. A new model of diffuse brain injury in rats. Part I: pathophysiology and biomechanics. J Neurosurg 1994;80:291–300. CrossRef
- Schmued LC, Hopkins KJ. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 2000;874(2):123–130. CrossRef
- Parra A, McGirt MJ, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: Methodological analysis. Neurol Res 2002;24:510–516. CrossRef
- Gao J, Wang H, Sheng H, et al. A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. Neurocritl Care 2006;4:25–31. CrossRef
- Hasan D, Schonck RSM, Avezaat CJJ, Tanghe HLJ, van Gijn J, van der Lugt PJM. Epileptic seizures after subarachnoid hemorrhage. Ann Neurol 1993;33:286–291. CrossRef
- Rose FC, Sarner M. Epilepsy after ruptured intracranial aneurysm. Brit Med J 1965;5426:18–21.
- Meek PD, Davis SN, Collins DM, et al. Guidelines for nonemergency use of parenteral phenytoin products: proceedings of an expert panel consensus process. Arch Intern Med 1999;159(22):2639–2644. CrossRef
- Rhoney DH, Tipps LB, Murry KR, Basham MC, Michael DB, Coplin WM. Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. Neurology 2000; 55:258–265.
- Holtzer CD, Reisner-Keller LA. Phenytoin-induced thrombocytopenia. Ann Pharmacother 1997;31:435–437.
- Ramsay RE, DeToledo J. Intravenous administration of fosphenytoin: options for the management of seizures. Neurology 1996; 46:17–19.
- Goldstein LB. Potential effects of common drugs on stroke recovery. Arch Neurol 1998;55:454–456. CrossRef
- Gidal BE, Baltes E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clincial trials. Epilepsy Res 2005;64(1–2):1–11. CrossRef
- Briggs DE, French JA. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf 2004;3(5):415–424. CrossRef
- Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101(26):9861–9866. CrossRef
- Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A SV2A). Proc Natl Acad Sci USA 1999;96(26):15,268–15,273. CrossRef
- Ignarro LJ, Byrns RE, Buga GM, Wood KS. Mechanisms of endothelium-dependent vascular smooth muscle relaxation elicited by bradykinin and VIP. Am J Physiol 1987;253:H1074-H1082.
- Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl 1988;6:S188-S191.
- Ito Y, Isotani E, Mizuno Y, Azuma H, Hirakawa K. Effective improvement of the cerebral vasospasm after subarachnoid hemorrhage with low-dose nitroglycerin. J Cardiovasc Pharmacol 2000; 35:45–50. CrossRef
- Pluta RM, Oldfield EH, Boock RJ. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg 1997;87:746–751.
- Wolf EW, Banerjee A, Soble-Smith J, Dohan FC, Jr., White RP, Robertson JT. Reversal of cerebral vasospasm using an intrathecally administered nitric oxide donor. J Neurosurg 1998;89:279–288. CrossRef
- Cardile V, Pavone A, Gulino R, Renis M, Scifo C, Perciavalle V. Expression of brain-derived neurotrophic factor (BDNF) and inducible nitric oxide synthase (iNOS) in rat astrocyte cultures treated with Levetiracetam. Brain Res 2003;976(2):227–233. CrossRef
- Dagonnier M, Laute MA, Pandolfo M, Manto M. Effects of levetiracetam on the production of nitric oxide-an in vivo study. J Neurol 2005;252(6):727–730. CrossRef
- Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage
Volume 5, Issue 1 , pp 71-78
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press
- Additional Links
- Subarachnoid hemorrhage
- traumatic brain injury
- posttraumatic epilepsy
- Industry Sectors
- Author Affiliations
- 1. Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Box 2900, 27710, Durham, NC
- 2. Department of Medicine (Neurology), Duke University Medical Center, Box 2900, 27710, Durham, NC
- 3. Department of Pharmacy, Duke University Medical Center, Box 2900, 27710, Durham, NC
- 4. Department of Anesthesiology, Duke University Medical Center, Box 2900, 27710, Durham, NC
- 5. Department of Histology and Embryology, North China Coal Medical College, Tangshan, Hebei, China